Physician profile
Nirupma B Rohatgi
NPI 1114029972
$2,218.23
in general payments reported to CMS, 2019-2025
17 companies · $700 in 2025
The $700 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $61.00 · 2021: $92.66 · 2022: $305 · 2023: $536 · 2024: $284 · 2025: $700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,519.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $526.47 | 2019-2025 | Dupixent |
| Optinose US, INC. | $311.82 | 2021-2024 | |
| Greer Laboratories, INC. | $248.25 | 2025 | Oralair |
| Genentech USA, INC. | $222.46 | 2019-2025 | Xolair |
| Astrazeneca Pharmaceuticals LP | $155.04 | 2023-2024 | Tezspire, Airsupra, Breztri |
| Amgen INC. | $126.70 | 2022-2023 | Tezspire |
| Genzyme Corporation | $122.48 | 2021-2024 | |
| Kaleo, INC. | $102.49 | 2019 | |
| Novartis Pharmaceuticals Corporation | $96.16 | 2025 | |
| Pfizer INC. | $61.62 | 2023-2025 | |
| Alk-Abello, INC | $61.00 | 2020 | |
| Glaxosmithkline, LLC. | $60.22 | 2022-2023 | Trelegy Ellipta |
| Incyte Corporation | $43.42 | 2022 | |
| Biocryst US Sales Co., LLC | $36.28 | 2025 | Orladeyo |
| Merck Sharp & Dohme LLC | $17.76 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $13.24 | 2024 | Cuvitru |
| Leo Pharma INC. | $12.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nirupma Rohatgi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.